CPIG
NRXP icon

Chicago Partners Investment Group’s NRX Pharmaceuticals NRXP Stock Holding History

Chicago Partners Investment Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$1.49K – 1660
2026
Q1 		$1.49K Buy
+500
New +$1.01K ﹤0.01% 1488

Other funds holding NRXP

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.99% 1-Year Est. Return

Chicago Partners Investment Group's NRXP Position: Q2 2026 in Review

Chicago Partners Investment Group increased its NRX Pharmaceuticals (NRXP) stake by 35% in Q2 2026, buying an estimated $39.3K and bringing the position to 46,388 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Chicago Partners Investment Group first reported a position in NRXP in Q3 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Chicago Partners Investment Group held 46,388 shares of NRX Pharmaceuticals worth $191K as of Q2 2026.
  • Chicago Partners Investment Group bought 11,909 NRX Pharmaceuticals shares in Q2 2026, an estimated $39.3K.
  • NRX Pharmaceuticals made up ﹤0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1432 holding.
  • Chicago Partners Investment Group first reported a position in NRX Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.